

Sabino De Placido

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/37175/publications.pdf>

Version: 2024-02-01

207
papers

8,493
citations

44069

48
h-index

58581

82
g-index

212
all docs

212
docs citations

212
times ranked

13312
citing authors

#	ARTICLE	IF	CITATIONS
1	Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene (<i>CYP19A1</i>) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. <i>Cancer Research</i> , 2022, 82, P3-09-03-P3-09-03.	0.9	0
2	Heterogeneity of SSTR2 Expression Assessed by ⁶⁸ Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1509-1514.	5.0	11
3	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103649.	4.4	9
4	Definition of High-Risk Early Hormone-Positive HER2 ⁻ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
5	Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment. <i>Genes</i> , 2022, 13, 682.	2.4	1
6	Prevalence of Sarcopenia in Women with Breast Cancer. <i>Nutrients</i> , 2022, 14, 1839.	4.1	9
7	Impaired seroconversion after SARS-COV-2 mRNA vaccine in patients with thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8588-8588.	1.6	0
8	Immunological signature of patients with thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8589-8589.	1.6	1
9	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191.	4.4	9
10	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103198.	4.4	35
11	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	5.2	331
12	Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie. <i>Frontiers in Oncology</i> , 2021, 11, 602523.	2.8	4
13	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17
14	Urologic malignancies: advances in the analysis and interpretation of clinical findings. <i>Future Science OA</i> , 2021, 7, FSO674.	1.9	24
15	Pneumonitis in patients with thymoma and Good's syndrome.. <i>Journal of Clinical Oncology</i> , 2021, 39, e20595-e20595.	1.6	0
16	Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. <i>World Journal of Clinical Oncology</i> , 2021, 12, 355-366.	2.3	8
17	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	2.8	41
18	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , 2021, 26, e1854-e1861.	3.7	16

#	ARTICLE	IF	CITATIONS
19	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	5.2	6
20	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
21	Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. <i>Cancers</i> , 2021, 13, 4939.	3.7	3
22	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	10.7	41
23	Assessment of Total, PTEN ⁺ , and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e286-e298.	1.9	18
24	BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. <i>Genes</i> , 2021, 12, 1917.	2.4	2
25	Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy. <i>Frontiers in Oncology</i> , 2021, 11, 754108.	2.8	6
26	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094797.	3.2	7
27	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020, 5, e000885.	4.5	9
28	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096872.	3.2	6
29	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	5.0	6
30	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515.	3.7	10
31	Toll-like receptors and COVID-19: a two-faced story with an exciting ending. <i>Future Science OA</i> , 2020, 6, FSO605.	1.9	96
32	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. , 2020, 8, e001154.		13
33	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	4.5	29
34	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59
35	Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy. <i>Oncology</i> , 2020, 98, 743-747.	1.9	33
36	Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 401-409.	2.5	27

#	ARTICLE	IF	CITATIONS
37	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. <i>Clinical Colorectal Cancer</i> , 2020, 19, 270-276.	2.3	0
38	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020, 20, 232.	2.6	6
39	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	2.8	6
40	Khorana score and thromboembolic risk in stage IIâ€“III colorectal cancer patients: a <i>post hoc</i> analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	6
41	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 408.	3.7	32
42	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
43	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	2.2	4
44	A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. <i>Frontiers in Oncology</i> , 2020, 10, 602153.	2.8	5
45	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102992.	4.4	28
46	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091.	1.8	7
47	Palbociclib added to ongoing endocrine therapy for hormone receptorâ€™positive HER2â€™negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020, 12, 456-460.	1.0	1
48	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 307-313.	5.9	38
49	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. <i>Cancers</i> , 2019, 11, 981.	3.7	29
50	Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1345-1352.	1.2	53
51	Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. <i>Breast Journal</i> , 2019, 25, 1310-1311.	1.0	4
52	Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2019, 33, 937-944.	2.2	35
53	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1259.	3.7	18
54	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131

#	ARTICLE	IF	CITATIONS
55	<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. OncoTargets and Therapy, 2019, Volume 12, 2989-2997.	2.0	23
56	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. European Journal of Cancer, 2019, 118, 178-186.	2.8	39
57	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. Gynecologic Oncology, 2019, 154, 83-88.	1.4	9
58	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37â298 women with early breast cancer in 26 randomised trials. Lancet, The, 2019, 393, 1440-1452.	13.7	260
59	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 421-432.	2.8	45
60	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. Oncologist, 2019, 24, 385-393.	3.7	23
61	Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma. Anti-Cancer Drugs, 2019, 30, 959-963.	1.4	2
62	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. Cancer Treatment Reviews, 2019, 73, 73-83.	7.7	88
63	Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch1âEGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells. Molecular Cancer Research, 2019, 17, 628-641.	3.4	6
64	Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2019, 37, e12549-e12549.	1.6	2
65	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2019, 37, e12528-e12528.	1.6	0
66	Anti-EGFR target therapy in advanced thymic epithelial tumors.. Journal of Clinical Oncology, 2019, 37, 8567-8567.	1.6	1
67	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncology, The, 2018, 19, 474-485.	10.7	59
68	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. Cancer Research, 2018, 78, 845-852.	0.9	169
69	Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. Menopause, 2018, 25, 657-662.	2.0	65
70	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. Breast, 2018, 38, 86-91.	2.2	27
71	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. European Urology Focus, 2018, 4, 874-879.	3.1	30
72	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2âPositive and Hormone ReceptorâPositive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. Journal of Clinical Oncology, 2018, 36, 2826-2835.	1.6	152

#	ARTICLE	IF	CITATIONS
73	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 342-349.	1.6	120
74	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients. <i>Medicine (United States)</i> , 2018, 97, e11254.	1.0	8
75	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 608.	2.8	160
76	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy). <i>Journal of Cellular Biochemistry</i> , 2018, 123, 101-107.	1.0	1
77	Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors. <i>Future Oncology</i> , 2018, 14, 1591-1599.	2.4	4
78	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018, 9, 189.	3.5	26
79	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018, 9, 19861-19873.	1.8	37
80	It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018, 18, 146.	2.6	16
81	Long term deficiency of vitamin D in germ cell testicular cancer survivors. <i>Oncotarget</i> , 2018, 9, 21078-21085.	1.8	5
82	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 832-836.	1.7	3
83	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608.	3.7	108
84	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017, 116, 1425-1435.	6.4	76
85	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Medicine (United States)</i> , 2017, 96, e6817.	1.0	4
86	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	2.8	38
87	Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. <i>Clinical Breast Cancer</i> , 2017, 17, 559-563.	2.4	12
88	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
89	2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 930-936.	1.2	118
90	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39

#	ARTICLE	IF	CITATIONS
91	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. Breast Care, 2017, 12, 290-294.	1.4	21
92	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. Breast, 2017, 31, 114-120.	2.2	49
93	The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncology, 2017, 13, 285-293.	2.4	55
94	Discordance in RAS Mutations between Primary Colon Tumor and Metastases: A Real Event or a Matter of Methodology?. International Journal of Biological Markers, 2017, 32, 474-477.	1.8	2
95	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. Scientific Reports, 2017, 7, 9388.	3.3	56
96	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. Journal of Cancer, 2017, 8, 2663-2668.	2.5	5
97	Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. International Journal of Molecular Sciences, 2017, 18, 2487.	4.1	20
98	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. Oncotarget, 2017, 8, 115709-115717.	1.8	18
99	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. Oncotarget, 2017, 8, 112816-112824.	1.8	3
100	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or 3rd) Line of Therapy. Journal of Clinical Oncology, 2017, 35, 487.	3.5	23
101	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. Medicine (United States), 2016, 95, e2754.	1.0	2
102	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO)., 2016, 4, .		0
103	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. Cancer Treatment Reviews, 2016, 46, 20-26.	7.7	87
104	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. Medicine (United States), 2016, 95, 14.	1.0	14
105	Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. BMC Cancer, 2016, 16, 375.	2.6	31
106	Approaches for targeting cancer stem cells drug resistance. Expert Opinion on Drug Discovery, 2016, 11, 1201-1212.	5.0	38
107	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. Expert Opinion on Biological Therapy, 2016, 16, 1387-1401.	3.1	22
108	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treatment Reviews, 2016, 50, 129-141.	7.7	81

#	ARTICLE	IF	CITATIONS
109	Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 18.	1.5	2
110	Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. <i>Menopause</i> , 2016, 23, 1108-1113.	2.0	75
111	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, .		18
112	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	2.5	14
113	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016, 12, 399-411.	2.4	39
114	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , 2016, 14, 470-481.	3.4	39
115	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016, 7, 40073-40084.	1.8	15
116	Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 127-132.	2.5	33
117	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. <i>Medicine (United States)</i> , 2015, 94, e1861.	1.0	43
118	The evolving landscape in advanced penile cancer. <i>Future Science OA</i> , 2015, 1, FSO9.	1.9	3
119	Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 452-456.	2.4	17
120	Third-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Medicine (United States)</i> , 2015, 94, e2297.	1.0	16
121	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. <i>BioMed Research International</i> , 2015, 2015, 1-14.	1.9	34
122	Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research. <i>Journal of Medical Ethics</i> , 2015, 41, 799-803.	1.8	6
123	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e2117.	1.0	45
124	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 534-541.	4.4	35
125	Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015, 41, 61-68.	7.7	48
126	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	1.6	361

#	ARTICLE	IF	CITATIONS
127	Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?. <i>Future Oncology</i> , 2015, 11, 975-981.	2.4	3
128	Features of aggressive breast cancer. <i>Breast</i> , 2015, 24, 594-600.	2.2	52
129	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 [×] 2 factorial, randomised phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1863-1872.	13.7	164
130	Nab-paclitaxel for the management of triple-negative metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 117-122.	1.4	8
131	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015, 26, 236-239.	1.4	7
132	Mechanisms of lapatinib resistance in HER2-driven breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 877-883.	7.7	125
133	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254.	2.4	1
134	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015, 11, 3091-3098.	2.4	17
135	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. <i>Oncotarget</i> , 2015, 6, 26090-26103.	1.8	37
136	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014, 10, 1353-1360.	2.4	23
137	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440.	5.0	94
138	Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	49
139	Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?. <i>Future Oncology</i> , 2014, 10, 845-850.	2.4	2
140	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. <i>Breast Cancer Research</i> , 2014, 16, R45.	5.0	56
141	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	7.4	25
142	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
143	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014, 23, 69-75.	2.2	92
144	Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?. <i>Clinical Colorectal Cancer</i> , 2014, 13, 185-191.	2.3	23

#	ARTICLE	IF	CITATIONS
145	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. World Journal of Clinical Cases, 2014, 2, 228.	0.8	18
146	Bevacizumab maintenance in metastatic colorectal cancer: How long?. World Journal of Clinical Cases, 2014, 2, 717.	0.8	0
147	Breast cancer subtypes according to body mass index and insulin resistance.. Journal of Clinical Oncology, 2014, 32, 571-571.	1.6	5
148	Risk factors for cancer-related venous thromboembolism in ambulatory patients.. Journal of Clinical Oncology, 2014, 32, e20625-e20625.	1.6	0
149	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. BMC Cancer, 2013, 13, 164.	2.6	19
150	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. Journal of Translational Medicine, 2013, 11, 161.	4.4	36
151	Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer. Combination Products in Therapy, 2013, 3, 25-37.	1.1	1
152	EGFR mutational status in penile cancer. Expert Opinion on Therapeutic Targets, 2013, 17, 501-505.	3.4	14
153	Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models. Clinical Cancer Research, 2013, 19, 138-147.	7.0	87
154	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. Breast, 2013, 22, 470-475.	2.2	13
155	Gene expression profiling in breast cancer: A clinical perspective. Breast, 2013, 22, 109-120.	2.2	73
156	Issues of banking breast cancer cells to generate mammospheres. Cell and Tissue Banking, 2013, 14, 153-158.	1.1	2
157	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. Anti-Cancer Drugs, 2013, 24, 980-985.	1.4	19
158	Doseâ€Dense FEC Followed by Doseâ€Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. Oncologist, 2013, 18, 924-925.	3.7	0
159	EMPACT Syndrome Associated with Phenobarbital. Dermatitis, 2013, 24, 37-39.	1.6	9
160	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. Future Oncology, 2013, 9, 889-897.	2.4	38
161	Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. Oncoimmunology, 2013, 2, e25123.	4.6	3
162	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. Tumori, 2013, 99, e131-e133.	1.1	2

#	ARTICLE	IF	CITATIONS
163	Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. <i>Molecular and Clinical Oncology</i> , 2013, 1, 726-732.	1.0	2
164	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013, 24, 84-89.	1.4	29
165	Combined Imaging With 18F-FDG-PET/CT and 111In-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors. <i>Clinical Nuclear Medicine</i> , 2013, 38, 354-358.	1.3	12
166	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 125.	1.9	23
167	Epithelialâ€“Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2526-2534.	4.1	194
168	Non-small cell lung cancer: from targeted therapy to tailored therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1817-1819.	1.8	2
169	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1079-1080.	1.8	2
170	Combination of docetaxel and cetuximab for penile cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 573-577.	1.4	29
171	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2012, 13, 1676-1686.	2.1	34
172	Cisplatin and 5â€“fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012, 110, E661-6.	2.5	76
173	A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1113-1119.	0.8	149
174	Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 960-972.	1.5	36
175	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 309-315.	2.3	44
176	Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13509-e13509.	1.6	1
177	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011, 13, R67.	5.0	188
178	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 449-455.	1.8	3
179	Phase II study of docetaxel reâ€“treatment in docetaxelâ€“pretreated castrationâ€“resistant prostate cancer. <i>BJU International</i> , 2011, 107, 234-239.	2.5	82
180	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 54-68.	4.4	79

#	ARTICLE	IF	CITATIONS
181	Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study. <i>European Urology</i> , 2011, 60, 1280-1284.	1.9	73
182	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 147-154.	2.5	23
183	Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 451-458.	2.5	31
184	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1455-1461.	2.3	24
185	Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1207-1213.	2.3	67
186	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1491-1497.	1.8	23
187	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	1.1	15
188	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010, 100, 311-319.	2.9	4
189	Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 906-911.	1.9	55
190	Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 611-617.	1.8	2
191	Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2010, 70, 983-1000.	10.9	98
192	Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer. <i>Oncology</i> , 2010, 78, 369-375.	1.9	26
193	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 2526.	3.3	27
194	Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer. <i>Oncology</i> , 2009, 77, 23-37.	1.9	47
195	Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4469-4474.	1.6	131
196	Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. <i>Cancer</i> , 2009, 115, 517-523.	4.1	19
197	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. <i>Anti-Cancer Drugs</i> , 2009, 20, 277-280.	1.4	11
198	Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer. <i>Cancer</i> , 2008, 112, 75-83.	4.1	83

#	ARTICLE	IF	CITATIONS
199	Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma. <i>Cancer</i> , 2008, 112, 1147-1152.	4.1	31
200	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180.	4.4	23
201	Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1578-1580.	0.7	57
202	Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. <i>European Urology</i> , 2008, 54, 1089-1096.	1.9	121
203	Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R60.	5.0	54
204	Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 44-53.	1.6	389
205	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3091-3100.	4.1	10
206	Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. <i>Tumori</i> , 2003, 89, 349-360.	1.1	6
207	FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. <i>Future Oncology</i> , 0, , .	2.4	0